Long non-coding RNAs in cutaneous biology and keratinocyte carcinomas

Minna Piipponen1,2 · Liisa Nissinen1,2 · Veli-Matti Kähäri1,2

Received: 20 December 2019 / Revised: 29 April 2020 / Accepted: 15 May 2020 / Published online: 27 May 2020 © The Author(s) 2020

Abstract

Long non-coding RNAs (lncRNAs) are a largely uncharacterized group of non-coding RNAs with diverse regulatory roles in various biological processes. Recent observations have elucidated the functional roles of lncRNAs in cutaneous biology, e.g. in proliferation and differentiation of epidermal keratinocytes and in cutaneous wound repair. Furthermore, the role of lncRNAs in keratinocyte-derived skin cancers is emerging, especially in cutaneous squamous cell carcinoma (cSCC), which presents a significant burden to health care services worldwide and causes high mortality as metastatic disease. Elucidation of the functions of keratinocyte-specific IncRNAs will improve understanding of the molecular pathogenesis of epidermal disorders and skin cancers and can be exploited in development of new diagnostic and therapeutic applications for keratinocyte carcinomas. In this review, we summarize the current evidence of functionally important IncRNAs in cutaneous biology and in keratinocyte carcinomas.

Keywords Skin cancer · Basal cell carcinoma · Cutaneous squamous cell carcinoma · Epidermis · Wound repair · Ultraviolet radiation

Introduction

Skin cancers are the most common cancer types globally with increasing incidence [1, 2]. Melanoma, basal cell carcinoma (BCC), and cutaneous squamous cell carcinoma (cSCC) are the three major types of skin cancer. Cumulative exposure to ultraviolet radiation (UVR) is a common risk factor for skin cancers, but they differ with respect to mutational profiles and alterations in cellular signaling pathways [3]. Melanoma originates from melanocytes, whereas BCC and cSCC originate from epidermal keratinocytes and are, therefore, called keratinocyte carcinomas (KC). The best preventive measure against skin cancer is avoiding excessive and cumulative exposure to sunlight and other sources of UVR. In addition, early detection and treatment is pivotal for the prognosis of the disease. The mortality rates for skin cancers vary between populations. However, taking into account the considerably higher incidence of KC over melanoma, it is estimated that the global mortality rate for all non-melanoma skin cancers (NMSCs) including BCC and cSCC, is even higher than for melanoma [4].

A significant proportion of human genome encodes non-coding RNAs (ncRNAs), including ribosomal RNA (rRNA) and transfer RNA (tRNA), and other functionally relevant ncRNAs, roughly categorized to small (sncRNAs) and long non-coding RNAs (lncRNAs) [5]. MicroRNAs (miRNAs) present an evolutionary conserved subgroup of sncRNAs deregulated in different cancers, including BCC and cSCC [6, 7]. LncRNAs are single-stranded RNA molecules larger than 200 nucleotides in size, lacking protein-coding capacity and sequence conservation [8]. It has become increasingly evident that they regulate a variety of cellular functions, and that aberrant expression of lncRNAs plays a role in various pathological conditions including cancer [9].

The mutational background for cSCC and BCC is well documented, and several driver mutations in protein coding genes have been identified [10–17]. These same driver gene mutations are also found frequently in epidermal keratinocytes in normal sun-exposed skin [18], indicating, that also
other factors, e.g. changes in non-coding genes and the microenvironment, are also necessary for development of cSCC [19]. Mutations in the non-coding regions of genome can affect chromatin structure, transcription factor binding, and gene expression [20]. Moreover, these mutations may alter expression or secondary structure of IncRNAs or interfere with IncRNA interaction with other regulatory factors [21]. The consequence of non-coding mutations in IncRNA expression and function in cutaneous carcinogenesis and skin cancer development is largely unknown. However, recent evidence suggests that IncRNAs participate in the complex cancer signaling network in skin malignancies. Elucidation of their role in cutaneous biology is likely to reveal new molecular targets for diagnostics and therapeutic intervention. In this review, we summarize the current findings of the function of IncRNAs in cutaneous biology and in keratinocyte carcinomas.

### Keratinocyte carcinomas

Keratinocyte carcinomas BCC and cSCC are the most common forms of skin cancer with increasing incidence globally [22, 23]. The primary cause for KCs is chronic exposure to UVR, and other important risk factors include immunosuppression, human papillomavirus infection, and chronic cutaneous ulceration [22–24]. While BCC is the most common human malignancy, cSCC accounts for the majority of deaths among KCs [25, 26]. In addition, a personal history of KCs is associated with a risk for other cancers [27]. In contrast to BCC, which rarely metastasizes, the risk of metastasis for cSCC is estimated as 1–4% and the prognosis of metastatic cSCC is poor [26]. Overall, the high prevalence of KCs poses a marked burden on health care worldwide and has a major impact on the patients’ quality of life [28].

Development of KC involves accumulation of several molecular and cellular changes. Both BCC and cSCC harbor a substantial mutational burden, mainly due to cumulative UV exposure typically observed as C→T transitions in the DNA [12–19]. Several studies using BCC and cSCC murine models suggest that these cancers arise from multiple cellular origins, e.g. from different stem cell populations in the basal layer of the epidermis, hair follicle bulge or sebaceous gland [29].

Despite a high frequency of UV-induced mutations, BCCs and cSCCs do not harbor many common genetic alterations, except inactivation of tumor suppressor p53 [12–19]. Several driver gene mutations have been identified for cSCC, resulting in constitutive activation of HRAS and inactivation of tumor suppressors p53 and NOTCH1 [12–16]. Conversely, BCC is strongly associated with aberrant activation of the Hedgehog signaling pathway due to loss of PTCH1 receptor function and activation of the G protein-coupled receptor SMO [17–19]. Like many other cancers, cSCCs and BCCs are associated with epigenetic deregulation and aberrant DNA methylation, which also contribute to cancer progression [30–34].

Actinic keratoses (AKs) are early precursors of cSCC and Bowen’s disease is in situ cSCC (cSCCIS), where atypical keratinocytes extend throughout the epidermis [35]. If left untreated, these lesions develop to invasive cSCCs. In general, patients with BCCs or resectable primary cSCCs have a good prognosis, whereas metastatic cSCC is associated with poor outcome [26]. Radiation and chemotherapy can be used for advanced and recurrent high-risk tumors that cannot be excised, especially those located in the facial area [36]. Recently, targeted therapies have been approved for therapy of advanced BCC and cSCC. Vismodegib, an inhibitor of Hedgehog pathway, is available for treatment of locally advanced BCC [37]. Immune checkpoint inhibitor, programmed cell death protein-1 (PD-1) blocking monoclonal antibody cemiplimab, has been approved for treatment of patients with locally advanced or metastatic cSCC [38]. Nevertheless, there is an urgent need for additional targeted therapies for advanced cSCCs and for prognostic biomarkers for predicting the risk of recurrence and metastatic potential of cSCC.

### Long non-coding RNAs

Long non-coding RNAs (IncRNAs) are single-stranded RNAs mainly transcribed by RNA polymerase II, which undergo post-transcriptional processing, such as 5′-capping, splicing and polyadenylation [8]. This way IncRNAs closely resemble messenger RNAs (mRNA), but they are not translated to proteins. Some IncRNAs are rapidly degraded after transcription, whereas others are extremely stable [39, 40]. A rapid turnover of IncRNAs enables a dynamic cellular response via specifically induced IncRNAs, for instance in DNA damage, immune response, and cellular differentiation [41–43].

IncRNAs are poorly conserved between species [44–46]. In general, IncRNAs are considered larger than 200 nucleotides in size. This division, however, is not strict, as some IncRNAs are less than 200 nucleotides in size, and some IncRNAs can function both as regulatory IncRNAs and can be processed to sncRNAs [47]. Classification of IncRNAs into distinct subgroups is commonly based on their genomic location.

Long intergenic or intervening non-coding RNAs (lin-cRNAs) are transcribed from distinct loci, often from their own promoters, whereas intronic IncRNAs are transcribed from intronic regions within protein-coding gene [45, 47]. Sense IncRNAs are transcribed from the sense strand also containing exons of protein-coding genes [47]. Natural
antisense transcripts (NATs) are transcribed from the anti-sense strand of a protein-coding gene, overlapping either exonic or intronic regions [47]. Bidirectional lncRNAs are produced divergently from the same promoter of a protein-coding gene. Circular RNAs (circRNA) are a recently discovered group of lncRNAs structurally different from most lncRNAs. They are produced by back splicing of precursor mRNAs or lncRNAs, resulting in covalently closed circular RNAs without polyadenylation, and they can originate from intronic or exonic transcripts [48].

LncRNAs are specifically expressed during normal physiological processes including cell differentiation and tissue development, whereas untimely and aberrant expression of lncRNAs in various pathological conditions is becoming evident [9–11]. Thus, alternative classification has been suggested, for instance by grouping them into lncRNAs regulating gene expression locally (cis) or in distance (trans) [49], or by other criteria such as subcellular localization, association with DNA-elements, or functional mechanism [50].

Molecular functions of IncRNAs

In general, the regulatory role of lncRNAs is based on binding to specific effector molecules by sequence complementarity or structural recognition to mediate gene expression. The single-stranded structure of lncRNAs and folding into unique secondary and tertiary structures gives them the ability to bind to RNA, DNA or proteins and this way control diverse cellular functions [8, 51, 52] (Fig. 1). lncRNAs typically exhibit a strict cell and tissue-specific expression and subcellular localization, indicating strictly controlled regulatory role for distinct lncRNAs [44, 53]. Specific localization of distinct lncRNAs to cytoplasm, nucleus, or other cellular compartments is likely to reflect their function (Fig. 1). In addition, some lncRNAs are secreted in extracellular vesicles and exosomes, and can exert their effect in adjacent cells and in cells in other tissues [54, 55]. In general, lncRNA mechanism of action can be divided into four main types: signals, guides, decoys, and scaffolds [51]. Simply, they can also be classified as nuclear lncRNAs in mediating gene transcription [56] or cytoplasmic lncRNAs controlling post-transcriptional events and mRNA stability [57] (Fig. 1).

LncRNAs in cutaneous biology

Regulation of epidermal differentiation by lncRNAs

The skin serves as a protective barrier against several environmental threats, including microbes, chemicals, and physical insults, and it also controls water loss and thermoregulation. Skin consists of several different cell types and stem cell populations, which co-operate to maintain and regenerate its structure and function [58]. The epidermal layer of skin is under continuous turnover, as the cells generated from the basal keratinocytes lose their proliferative capacity, commit to terminal differentiation, and move towards skin surface [59]. During this process, keratinocytes undergo major morphological and mechanical changes due to spatiotemporal alteration in their transcriptional program [60]. Several markers for keratinocyte differentiation have been identified and the chromatin dynamics play a crucial role during this process [61–63].

Transcriptional changes during differentiation of epidermal keratinocytes also involve alterations in the expression of non-coding RNAs and accordingly specific lncRNAs have been implicated in keratinocyte differentiation [64, 65] (Fig. 2). Differentiation antagonizing non-protein coding RNA (DANCR) is downregulated during terminal differentiation of keratinocytes and it is required for maintaining the undifferentiated phenotype of epidermal progenitor cells [66]. DANCR is a negative regulator of MAF and MAFB transcription factors, which are important regulators of differentiation in various cell types [67]. DANCR represses the expression of MAF and MAFB epigenetically by guiding a chromatin-modifying protein complex to the promoters of their genes [66]. In contrast to DANCR, terminal differentiation-induced ncRNA (TINCR) is highly expressed in differentiating keratinocytes specifically in the suprabasal layers of human epidermis [68]. TINCR promotes keratinocyte differentiation by stabilizing mRNAs coding for proteins involved in keratinocyte differentiation e.g. transcription factors MAF and MAFB, together with an RNA-binding protein STAU1 [68]. Together, DANCR and TINCR are able to regulate the expression of a broad range of genes in keratinocytes and this way function as pivotal regulators of epidermal differentiation.

The expression of LINCC00941 is downregulated upon keratinocyte differentiation, and it antagonizes the function of small proline rich protein 5 (SPRR5), which promotes differentiation of keratinocytes [69]. The expression of β1-adjacent long non-coding RNA (BLNCR) is also downregulated during keratinocyte differentiation, preceding downregulation of ITGB1, which codes for integrin β1, an epidermal stem cell marker adjacent to BLNCR gene [70, 71]. BLNCR and ITGB1 are both transcriptionally regulated by transcription factors p63 and AP-1, and loss of BLNCR and ITGB1 expression may be an early event resulting in loss of proliferative capacity of keratinocytes and in subsequent terminal differentiation [71].

Progenitor renewal associated non-coding RNA, (PRANCR), is one of the most recently characterized lncRNAs involved in epidermal homeostasis [72]. Depletion of PRANCR leads to reduced proliferative capacity and differentiation of keratinocytes. PRANCR regulates the
Fig. 1 Molecular functions of lncRNAs. Nuclear lncRNAs can regulate epigenetic changes by a decoying or b guiding chromatin-modifying complexes to specific genomic loci. c lncRNAs can induce chromosomal looping to control gene expression by simultaneously binding to protein complexes or specific DNA elements. LncRNAs can inhibit gene transcription d by blocking a transcription factor binding site or f by binding to RNA polymerase. g LncRNAs may contribute to transcriptional activation by guiding transcription factors or other co-factors to gene promoters. e LncRNAs can regulate alternative splicing that can occur by lncRNA binding to mRNA and blocking the splice-site. LncRNAs can also recruit and guide splicing factors to the sites of transcription. Cytoplasmic lncRNAs can regulate mRNA stability h directly by binding to mRNAs or i indirectly by sequestering miRNAs by complementary base pairing. j Some lncRNAs can be secreted to extracellular vesicles or exosomes allowing them to mediate intercellular signaling. k LncRNAs can serve as scaffolds to promote the assembly of active ribonucleoprotein complexes in the cytoplasm or nucleus. l LncRNAs can aid intracellular translocation of proteins

© Springer
expression of several genes coding for cell cycle regulators, including E2F transcription factor target genes [72]. In addition, H19 imprinted maternally expressed transcript (H19) and SCC misregulated transcript-2 (SMRT-2) are recently identified IncRNAs induced during differentiation of epidermal keratinocytes [73, 74]. Depletion of SMRT-2 results in repression of several genes associated with epidermal differentiation and development [74]. These genes are also regulated by zinc finger protein 750 (ZNF750) and Kruppel like factor 4 (KLF4), suggesting that SMRT-2 functions upstream of the ZNF750-KLF4-axis [74]. ZNF750 functions downstream of p63 in driving epidermal differentiation by upregulating KLF4 [75]. Moreover, ZNF750 upregulates expression of lncRNA TINCR [76].

Taken together, these observations provide a regulatory link between SMRT-2, ZNF750 and TINCR in regulation of epidermal keratinocyte differentiation. As aberrant keratinocyte differentiation and stem-cell characteristics are involved in KC tumor development [77, 78], it is not surprising that the expression of keratinocyte differentiation inducing IncRNAs, SMRT-2 and TINCR, are strongly downregulated in cSCC [66, 74, 79]. Many of the IncRNAs associated with epidermal differentiation listed here are not implicated in cSCC and it will be important to investigate their mechanistic role in progression of cutaneous cancers.

**LncRNAs in cutaneous wound repair**

Cutaneous wound repair is a complex and strictly controlled process, which involves co-operation of several different cell types, including keratinocytes, fibroblasts, endothelial cells, and inflammatory cells [80]. Delayed wound healing resulting in chronic ulcers is usually associated with an underlying condition, such as insufficient arterial or venous circulation, diabetes or prolonged inflammation [80]. Chronic wounds also carry a risk of developing to cSCC [81].

The role of IncRNAs in normal wound repair or in pathogenesis of chronic ulcers is largely unknown. LncRNA expression profile in Marjolin ulcer, a rare, aggressive type of cSCC that evolves in scars or chronic wounds has been reported, but functional characterization of the IncRNAs in this condition is lacking [82]. Growth arrest-specific 5 lncRNA (GAS5) is a repressor of glucocorticoid receptor expression, which serves as a tumor suppressor in many cancers [83]. GAS5 has been shown to promote wound healing by inducing epithelialization and angiogenesis via c-myc inhibition [84]. Metastasis associated lung adenocarcinoma
expression of its target genes [90]. Wound and keratinocyte migration-associated lncRNA 1 and 2 (WAKMAR1 and WAKMAR2) are two recently identified lncRNAs, which play an important role in cutaneous wound repair [90, 91]. Expression of WAKMAR1 is highly upregulated in keratinocytes during wound repair and its expression stimulates keratinocyte migration and wound re-epithelization [90]. Expression of both WAKMAR1 and WAKMAR2 is induced by TGF-β and downregulation of their expression inhibits migration of keratinocytes, resulting in delayed wound re-epithelization [90, 91]. Accordingly, the expression of both WAKMAR1 and WAKMAR2 is reduced in keratinocytes in the edge of chronic wounds in vivo [90, 91]. Moreover, upregulation of WAKMAR2 expression inhibits production of inflammatory chemokines by keratinocytes, and this way promotes wound healing [91]. WAKMAR1 exerts its function by sequestering DNA methyltransferases, resulting in upregulation of the expression of E2F1 transcription factor and subsequent regulation of the expression of its target genes [90].

Regulation of lncRNAs by UVR

Exposure of skin to UVR induces several cellular responses. Activation of the inflammatory response manifesting as erythema in skin is an acute response after UV exposure [92]. UVR induces DNA damage in epidermal keratinocytes, which triggers a stress response, activation of p53 and DNA repair [93]. UV-induced DNA damage leads to systemic immunosuppression [94–96] which is exploited in treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis [97].

UVR leads to altered lncRNA expression in epidermal keratinocytes [98], melanocytes [99] and dermal fibroblasts in culture [100–103]. The biological response of skin to UVA and UVB is distinct due to their different penetration to the skin and they trigger distinct expression pattern of lncRNAs in HDFs [101]. It is possible, that some of these lncRNAs play a role in the early cellular stress response or acute inflammation following exposure to UV. Also, several UV-regulated lncRNAs in keratinocytes show a similar expression trend in cSCC and BCC, suggesting a role for them in epidermal carcinogenesis [98].

A subset of UV-induced lncRNAs has been functionally characterized [102–105]. In keratinocytes, the expression of lincRNA-p21 is markedly induced by UVB through a p53-dependent mechanism and it exerts a tumor suppressive role by triggering UVB-induced apoptosis and cell cycle arrest [105]. Accordingly, a tumor suppressive function for lincRNA-p21 has been reported in head and neck SCC [106]. Psoriasis susceptibility-related RNA gene induced by stress (PRINS) is a lncRNA induced by UVB and other stress signals, such as serum starvation or translational inhibition in HaCaT cells, an epidermal keratinocyte derived cell line, which lacks functional p53 [104]. Elevated expression of PRINS in psoriatic epidermis has also been reported, suggesting a role for PRINS in pathogenesis of psoriasis [104].

Vitamin D is photochemically synthesized in the skin by UVB and recent findings support a cancer protecting role for vitamin D [107]. Interestingly, keratinocytes lacking vitamin D receptor show a distinct lncRNA expression pattern with increased expression of oncogenic lncRNAs and decreased expression of tumor-suppressive lncRNAs, including lincRNA-p21 [108]. It appears, that UVR plays a dual role in skin by inducing the innate immune response, but predisposing to systemic immunosuppression and genomic mutations [1, 92, 97]. It is not known, what is the feasible level of UV exposure and to what extent lncRNAs can mediate the balance between skin homeostasis and carcinogenesis.

LncRNAs in keratinocyte carcinomas

The UV-induced alteration of lncRNA expression in epidermal cells suggests that some of these lncRNAs exert a protective role against carcinogenesis by triggering UV-induced early stress response [98–105] (Table 1). On the other hand, some of them may play a role at the early stage of epidermal carcinogenesis and loss of some differentiation-associated lncRNAs may serve as markers for tumor initiation. In keratinocyte carcinomas, particularly in cSCCs, several lncRNAs are differentially expressed as compared to normal skin or keratinocytes, suggesting a role for them in cSCC progression [109, 110]. Some of the deregulated lncRNAs may function in signaling pathways, which are already mutationally activated or suppressed in cSCC. On the other hand, it is likely that some of these lncRNAs are targeted by UV-induced mutations or by genomic alterations within the lncRNA gene itself, as has been observed in several cancer cell lines [111, 112]. As none of the BCC-associated lncRNAs have been functionally characterized so far, we will focus on lncRNAs implicated in cSCC (Table 1).

Aberrant activation of the ERK1/2 MAPK pathway is one of the central drivers in the molecular pathogenesis of cSCC [113–115]. ERK1/2 pathway is activated by UVA radiation [116]. Moreover, mutational activation of epidermal growth factor receptor (EGFR) results in sustained activation of the RAS-RAF-MEK-ERK signaling pathway and promotes cutaneous carcinogenesis [117].
Long non-coding RNAs in cutaneous biology and keratinocyte carcinomas

PICSAR plays a tumorigenic role in cSCC

p38-inhibited cutaneous squamous cell carcinoma-associated lncRNA (PICSAR) represents the earliest evidence of a functionally characterized lncRNA in cSCC [110]. The expression of PICSAR is upregulated in cSCC tumor cells in culture and in vivo compared to normal human epidermal keratinocytes (NHEKs) and normal skin [110]. Elevated expression of PICSAR was also noted in vivo in actinic keratosis and cSCC in situ, suggesting a role for PICSAR at the early stage of epidermal carcinogenesis [110]. Silencing of PICSAR expression potently suppresses growth of human cSCC xenografts [110]. Interestingly, PICSAR serves as a regulatory link between p38 and ERK1/2 mitogen-activated protein kinase (MAPK) pathways (Fig. 3a). Inhibition of p38 activity induces PICSAR expression and PICSAR promotes cSCC cell proliferation by promoting ERK1/2 activity via downregulation of dual specificity phosphatase DUSP6 [110]. In addition, PICSAR potently regulates cell adhesion and migration by regulating integrin expression [118], and may this way contribute to cSCC progression and invasion (Fig. 3a).

MALAT1 and LINC00520 play opposite roles in cSCC

MALAT1 is a lncRNA, which has been reported to be deregulated in different types of cancer [85]. Elevated expression of MALAT1 was recently reported in cSCC tumors and it was shown that the expression in cSCC cells is induced by UVB [119]. MALAT1 promotes proliferation, migration, and invasion of cSCC cells and growth of cSCC tumors in vivo and suppresses apoptosis of cSCC cells [119].

Table 1 Long non-coding RNAs with a potential role in cSCC or BCC development

| LncRNA         | Expression                  | Function                                                                 | References |
|----------------|-----------------------------|--------------------------------------------------------------------------|------------|
| TINCR          | Downregulated in cSCC      | Promotes human epidermal differentiation by stabilization of mRNAs coding for differentiation specific genes   | [68]       |
| SMRT-2         | Downregulated in cSCC      | Induced during keratinocyte differentiation. Knockdown in human organotypic skin downregulates several differentiation specific genes, including ZNF750 and KLF4 | [74]       |
| LINC00520      | Downregulated in cSCC      | Inhibits cSCC progression by downregulating expression of EGFR and its downstream targets, e.g. PI3K, AKT, and VEGF | [123]      |
| PICSAR         | Upregulated in cSCC        | Promotes cSCC progression by activating ERK1/2 by downregulating DUSP6. Decreases cSCC cell adhesion and increases cSCC cell migration by downregulating integrin expression | [110, 118] |
| PRECSIT        | Upregulated in cSCC        | Promotes cSCC cell invasion through STAT3-mediated upregulation of production of MMP-13, MMP-3, MMP-1, and MMP-10 | [129]      |
| LINC00319      | Upregulated in cSCC        | Increases cSCC cell growth, migration, and invasion. Suppresses apoptosis by upregulating cyclin-dependent kinase 3 via miR-1207-5p decoy | [130]      |
| LINC01048      | Upregulated in cSCC        | Interacts with TAF15 transcription factor to induce YAP1 transcription and tumorigenic function via Hippo signaling pathway | [126]      |
| MALAT1         | Upregulated in cSCC        | Positively regulates EGFR protein expression via c-MYC and KTN1           | [119]      |
| lincRNA-p21    | Induced in mouse and human keratinocytes by UVB | Tumor suppressive role by triggering UVB-induced apoptotic death | [105]      |
| AK144841       | Induced in mouse DMBA/TPA-induced cSCC | Downregulates several anticancer and cell differentiation genes in mouse | [79]      |
| H19, Hottip, Nespas, mHOTAIR, MALAT1, SRA | Upregulated in vitamin D receptor (VDR) deleted mouse keratinocytes and epidermis | Potential oncogenes in skin cancer progression | [108]  |
| Kcnq1ot1, lincRNA-p21, Foxn2-as, Glt2-as, H19-as | Inhibited in VDR-deleted mouse keratinocytes and epidermis | Potential tumor suppressors in skin cancer formation | [108]  |
| H19, CASC15, SPRY4-IT | Upregulated in BCC | Potential oncogenes in BCC | [131]  |
Mechanistically, $MALAT1$ interacts with c-Myc to activate transcription of kinectin 1 ($KTN1$) gene, which is one of the top downregulated genes after $MALAT1$ depletion. Knockdown of $MALAT1$ also results in decreased level of EGFR protein, but not EGFR mRNA [119]. These results suggest that $MALAT1$ contributes to cSCC pathogenesis by upregulating EGFR protein levels via c-Myc and $KTN1$ [119].

Marked expression of lncRNA $AK144841$ has been noted in chemically (DMBA/TPA) induced mouse cSCCs compared to healthy skin [79]. The histology and the genomic background of these tumors are very similar to human cSCCs [120]. Sustained activation of HRAS, which is caused by highly carcinogenic DMBA, results in marked induction of EGFR and its ligands in cSCC mouse model [121, 122]. In this regard, induction of $AK144841$ in murine cSCC may be related to EGFR activation. A potential human ortholog with homology to $AK144841$ has been shown to be expressed at high level in cSCC cell lines compared to NHEKs suggesting, that it may be involved in human cSCC progression [79].

Downregulation of $LINC00520$ has been noted in A431 cSCC cell line, compared to NHEKs, and overexpression of $LINC00520$ in A431 cells results in suppression of tumor growth and lymph node metastasis [123]. A431 cells express high levels of EGFR [124]. Reduced expression of EGFR and its downstream targets, PI3K, AKT, VEGF, MMP-2, and MMP-9 was noted in A431 cells overexpressing $LINC00520$, whereas an opposite effect was noted after $LINC00520$ depletion [123]. Altogether, these results suggest that $LINC00520$ plays a tumor suppressive role in cSCC by targeting EGFR [123].

**TINCR and SMRT-2 are potential tumor suppressors in cSCC**

Poor differentiation of cSCC is associated with risk for metastasis and poor prognosis [77, 78]. **TINCR** and **SMRT-2** both promote differentiation of keratinocytes and may this way serve in a protective role in keratinocyte carcinogenesis [68, 74]. Accordingly, decreased expression of **TINCR** and **SMRT-2** has been noted in human cSCCs [68, 74], and a notable decrease in **TINCR** expression has been reported in DMBA/TPA-induced murine cSCC tumors compared to normal skin [79]. In addition, marked suppression of **SMRT-2** expression has been noted in Ras-driven human organotypic epidermal neoplasia [74]. Together, these two lncRNAs may function as potential tumor suppressors in cSCC. In this context, it is interesting that ZNF750 which upregulates the expression of **TINCR** in keratinocytes, was recently shown to exert a tumor-suppressive role in SCCs of head and neck, lung, cervix, and skin [76].
LINCO1048 and Hippo pathway in keratinocyte carcinoma

Hippo pathway is a well-conserved signaling pathway, which is important in skin development, cutaneous homeostasis and tissue regeneration, and aberrant Hippo signaling has been noted in non-melanoma skin cancers [125]. Recently, upregulation of a previously unknown IncRNA, LINCO1048, was reported in cSCC associated with lower overall survival of cSCC patients [126]. LINCO1048 promotes cSCC cell growth via the Hippo pathway [126]. Depletion of LINCO1048 regulates the levels of the downstream effectors of the Hippo signaling, including yes-associated protein 1 (YAP1) and transcriptional co-activator with PDZ-binding motif (TAZ). Mechanistically, LINCO1048 interacts with transcription factor TAF15 to promote transcription of YAP1 gene [126]. Accordingly, YAP1 and TAZ function as oncogenes in many cancers, including BCC and cSCC [127, 128]. Together these results provide interesting new evidence for the role of LINCO1048/TAF15/YAP1-axis in cSCC progression.

PRECSIT and LINCO0319 regulate invasion of cSCC

p53-regulated carcinoma-associated STAT3-activating long intergenic non-protein coding transcript (PRECSIT) is a recently identified IncRNA with elevated expression in cSCC [129]. PRECSIT is a nuclear-enriched IncRNA downregulated by p53 signaling, and a high level of PRECSIT expression is associated with the absence of functional p53 in cSCC tumor cells in vivo [129]. Depletion of PRECSIT inhibits cSCC cell invasion by downregulating STAT3 expression and activation, and production of matrix metalloproteinases (MMPs), MMP-13, MMP-3, MMP-1, and MMP-10 [129], suggesting a tumor-promoting function for PRECSIT (Fig. 3b). These results provide interesting new evidence that p53/PRECSIT/STAT3 axis regulates the expression of invasion proteinases in the MMP gene cluster in 11q22.3: MMP-13/MMP-3/MMP-1/MMP-10.

LINCO0319 is a recently identified IncRNA with elevated expression in cSCC shown to correlate with larger tumor size and lymphovascular invasion of cSCC [130]. LINCO0319 promotes cSCC cell migration and invasion, and upregulates expression of MMP-2, MMP-9, and markers for epithelial–mesenchymal transition, E-cadherin, and vimentin [130]. PRECSIT regulates the invasion of cSCC cells specifically without affecting cell growth [129], whereas LINCO0319 has an anti-apoptotic function and promotes cSCC cell proliferation via miRNA-mediated mechanism [130].

Concluding remarks

The role of IncRNAs in epidermal biology is slowly emerging. The recent findings summarized here elucidate the functional role of IncRNAs in physiological conditions and keratinocyte cancer development, specifically in cSCC (Fig. 2, Table 1). It is noteworthy, that none of the BCC-associated IncRNAs have been functionally characterized yet. Moreover, considering UVR as a common nominator for the development of cSCC and BCC, it remains unclear whether they share the same UV-regulated IncRNAs. These cancers have distinct mutational background and different oncogenic signaling pathways. Therefore, it is likely that there are also specific IncRNAs which, by function, are associated with either cSCC or BCC development by cooperating with various signaling molecules to mediate the expression of tumor promoting or tumor suppressing genes. LncRNAs present great potential in developing new diagnostic and therapeutic approaches. Along with conventional molecular markers, distinct IncRNA expression signature may provide better diagnostic accuracy of the disease. Moreover, therapeutic targeting of tumorigenic IncRNAs may enhance the efficacy of cancer therapy.

Acknowledgements Open access funding provided by University of Turku (UTU) including Turku University Central Hospital. The original work of authors has been supported by grants from the Finnish Cancer Research Foundation, The Cancer Society of South-West Finland, Jane and Aatos Erkkö Foundation, Sigrid Jusélius Foundation, The state research funding of the Turku University Hospital (project 13336), The Kymenlaakso Regional Fund of the Finnish Cultural Foundation, Ida Montin Foundation, Instrumentarium Science Foundation, The Paulo Foundation, The Maud Kuistila Memorial Foundation, University of Turku Graduate School Funding and Turku University Foundation.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Asgari MM, Moffet HH, Ray GT, Quesenberry CP (2015) Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998–2012. JAMA Dermatol 151:976–981. https://doi.org/10.1001/jamadermatol.2015.1188
2. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM (2015) Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US Population, 2012. JAMA Dermatol 151:1081–1086. https://doi.org/10.1001/jamadermatol.2015.1187

3. Liu-Smith F, Jia J, Zheng Y (2017) UV-induced molecular signaling differences in melanoma and non-melanoma skin cancer. Adv Exp Med Biol 996:27–40. https://doi.org/10.1007/978-3-319-56017-5_3

4. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953. https://doi.org/10.1002/ijc.31937

5. Morris KV, Mattick JS (2014) The rise of regulatory RNA. Nat Rev Genet 17:47–62. https://doi.org/10.1038/nrg.2015.10

6. García-Sancha N, Corchado-Cobos R, Pérez-Losada J, Cañueto RE, Tsai KY, Curry JL, Tetzlaff MT, Lai SY, Yu J, Muzny DM, Phillips CA, Good諾 N, Kähäri VM (2019) Complement system in cutaneous squamous cell carcinoma. J Invest Dermatol 134:213–220. https://doi.org/10.1016/j.jic.2018.11.006

7. Syed DN, Lall RK, Mukhtar H (2015) MicroRNAs and photocarcinogenesis. Photochem Photobiol 91:173–187. https://doi.org/10.1111/php.12346

8. Quinn JJ, Chang HY (2016) Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 17:47–62. https://doi.org/10.1038/nrg.2015.1187

9. Schmitt AM, Chang HY (2016) Long noncoding RNAs in cancer pathways. Cancer Cell 29:452–463. https://doi.org/10.1016/j.ccell.2016.03.010

10. Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RS, Tsai KY, Curry JL, Tetzlaff MT, Lai SY, Yu J, Muzny DM, Doddapaneni H, Shinbrot E, Covington KR, Zhang J, Seth S, Caulin C, Clayman GL, El-Naggar AK, Gibbs RA, Weber RS, Myers JN, Wheeler DA, Frederick MJ (2014) Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 20:6582–6592. https://doi.org/10.1158/1078-0432.CCR-14-1768

11. Inman GJ, Wang J, Nagano A, Alexandrov LB, Purdie KJ, Taylor RG, Al-Rohil RN, Tarasen AJ, Carlson JA, Wang K, Johnson A, Tong S, Kim S, Aifantis I, Michielin O, de Sauvage FJ, Antonarakis SE, Nikolaev SI (2016) Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet 48:398–406. https://doi.org/10.1038/ng.3525

12. Jayaraman SS, Rayhan DJ, Hazany S, Kolodny MS (2014) Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol 134:213–220. https://doi.org/10.1038/jid.2013.276

13. Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, Wedge DC, Fullam A, Alexandrov LB, Tubio JM, Stebbings L, Menzies A, Wida S, Stratton MR, Jones PH, Campbell PJ (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348:880–886. https://doi.org/10.1126/science.aaa6806

14. Nissinen L, Farshchian M, Rihilik P, Kähäri VM (2016) New perspectives on role of tumor microenvironment in progression of cutaneous squamous cell carcinoma. Cell Res 26:691–702. https://doi.org/10.1037/00441-016-2457-z

15. Yang J, Adli M (2019) Mapping and making sense of noncoding mutations in the genome. Cancer Res 79:4309–4314. https://doi.org/10.1158/0008-5472.CAN-19-0905

16. Gao P, Wei GH (2017) Genomic insight into the role of IncRNA in cancer susceptibility. Int J Mol Sci 18:E1239. https://doi.org/10.3390/ijms18061239

17. Nehal KS, Bichakjian CK (2018) Update on keratinocyte carcinomas. N Engl J Med 379:363–374. https://doi.org/10.1056/NEJMra1708701

18. Nagarajan P, Asgari MM, Green AC, Guhan SM, Arron ST, Proby CM, Rollison DE, Harwood CA, Toland AE (2019) Keratinocytic carcinomas: current concepts and future research priorities. Clin Cancer Res 25:2379–2391. https://doi.org/10.1158/1078-0432.CCR-18-1122

19. Nissinen L, Knuttila J, Rahmati Nezhad P, Viiklepp E, Riihilä P, Kähäri VM (2019) Complement system in cutaneous squamous cell carcinoma. Int J Mol Sci 20:3550. https://doi.org/10.3390/ijms20163550

20. Lomas A, Leonardi-Bee J, Bath-Hextall F (2012) A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 166:1069–1080. https://doi.org/10.1111/j.1365-2133.2012.10830.x

21. Burton KA, Ashack KA, Khachemoune A (2016) Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease. Am J Clin Dermatol 17:491–508. https://doi.org/10.1007/s40257-016-0207-3

22. Small J, Barton V, Peterson B, Alberg AJ (2016) Keratinocyte carcinoma as a marker of a high cancer-risk phenotype. Adv Cancer Res 130:257–291. https://doi.org/10.1016/bs.acr.2016.01.003

23. Gao P, Wei GH (2017) Genomic insight into the role of IncRNA in cancer susceptibility. Int J Mol Sci 18:E1239. https://doi.org/10.3390/ijms18061239

24. Rodriguez-Paredes M, Bormann F, Raddatz G, Gutekunst J, Lucena-Porcel C, Köhler F, Wurzer E, Schmidt K, Gallinat S, Wenck H, Röwert-Huber J, Denisova E, Feuerbach L, Park J, Brors B, Herpel E, Lindl I, Hofmann TG, Winnefeld M, Lyko F (2018) Methylation profiling identifies two subclasses of squamous cell carcinoma related to distinct cells of origin. Nat Commun 9:577. https://doi.org/10.1038/s41467-018-03025-1

25. van der Velden AR, Irizarry RA, Hansen KD, Garza LA, Runarsson A, Li X, Chien AL, Wang TS, Leung SG, Kang S, Feinberg AP
(2015) Age and sun exposure-related widespread genomic blocks of hypomethylated in nonmalignant skin. Genome Biol 16:80. https://doi.org/10.1186/s13059-015-0644-y

32. Yang Y, Wu R, Sargsyan D, Yin R, Kuo HC, Yang I, Wang L, Cheng D, Wang C, Li S, Hudliker R, Lu Y, Kong AN (2019) UVB drives different stages of epigenome alterations during progression of skin cancer. Cancer Lett 449:20–30. https://doi.org/10.1016/j.canlet.2019.02.010

33. Brinkhuizen T, van den Hurk K, Wnepenninkx VJ, de Hoon JP, van Marion AM, Vecek J, van Engeland M, van Steensel MA (2012) Epigenetic changes in basal cell carcinoma affect SHH and WNT signaling components. PLoS ONE 7:e51710. https://doi.org/10.1371/journal.pone.0051710

34. Rao RC, Chan MP, Andrews CA, Kahana A (2018) Epigenetic markers in basal cell carcinoma: universal themes in oncogenesis and tumor stratification?—a short report. Cell Oncol (Dordr) 41:693–698. https://doi.org/10.1007/s13402-018-0402-8

35. Cockerell CJ (2000) Histopathology of incipient intraepidermal squamous cell carcinoma (“actinic keratosis”). J Am Acad Dermatol 42:11–17. https://doi.org/10.1067/jAAD.2000.103344

36. Que SKT, Zwald FO, Schmults CD (2018) Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J Am Acad Dermatol 78:249–261. https://doi.org/10.1016/j.jaad.2017.08.058

37. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedman PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366:2171–2179. https://doi.org/10.1056/NEJMoa1113713

38. Clark MB, Johnston RL, Inostroza-Ponta M, Fox AH, Fortini E, Ayupe AC, Tahira AC, Camargo L, Beckedorff FC, Verjovski-Almeida S, Sánchez Y, Segura V, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG (2018) PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379:341–351. https://doi.org/10.1056/NEJMoa1805131

39. Clark MB, Johnston RL, Inostroza-Ponta M, Fox AH, Fortini E, Moscato P, Dinger ME, Mattick JS (2012) Genome-wide analysis of long noncoding RNA stability. Genome Res 22:885–898. https://doi.org/10.1101/gr.130173.111

40. Ayupe AC, Tahira AC, Camargo L, Beckedorff FC, Verjovski-Almeida S, Reis EM (2015) Global analysis of biogenesis, stability and sub-cellular localization of lncRNAs mapping to intragenic regions of the human genome. RNA Biol 12:872–897.

41. Sánchez Y, Segura V, Marín-Béjar O, Athie A, Marchese FP, González J, Bujanda L, Guo S, Matheu A, Huarte M (2015) Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature. Nat Commun 5:5812. https://doi.org/10.1038/ncomms6812

42. Carpenter S, Aiello D, Atianand MK, Ricci EP, Gandhi P, Hall LL, Byron M, Mons B, HenryBezy M, Lawrence JB, O’Neill LA, Moore MJ, Caffrey DR, Fitzgerald KA (2013) A long non-coding RNA mediates both activation and repression of immune response genes. Science 341:789–792. https://doi.org/10.1126/science.1240925

43. Fico A, Fiorenzano A, Pascale E, Patriarca EJ, Minchiotti G (2019) Long non-coding RNA in stem cell pluripotency and lineage commitment: functions and evolutionary conservation. Cell Mol Life Sci 76:1459–1471. https://doi.org/10.1007/s00018-018-0300-z

44. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Vee ravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P, Brown JB, Lipovich L, Gonzalez JM, Thomas M, Davis CA, Sniekhatar R, Gingeras TR, Hubbard TJ, Notredame C, Harrow J, Guigó R (2012) The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 22:1775–1789. https://doi.org/10.1101/gr.132159.111

45. Ransohoff JD, Wei Y, Khavari PA (2018) The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol 19:143–157. https://doi.org/10.1038/nrm.2017.104

46. Pang KC, Frith MC, Mattick JS (2006) Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function. Trends Genet 22:1–5. https://doi.org/10.1016/j.tig.2005.10.003

47. Ma L, Bajic VB, Zhang Z (2013) On the classification of long non-coding RNAs. RNA Biol 10:925–933. https://doi.org/10.4161/rna.24604

48. Barrett SP, Salzman J (2016) Circular RNAs: analysis, expression and potential functions. Development 143:1838–1847. https://doi.org/10.1242/dev.128074

49. Kopp F (2018) Mendell JT (2018) Functional classification and experimental dissection of long noncoding RNAs. Cell 172:393–407. https://doi.org/10.1016/j.cell.2018.01.011

50. St Laurent G, Wahlestedt C, Kapranov P (2015) The Landscape of long noncoding RNA classification. Trends Genet 31:239–251. https://doi.org/10.1016/j.tig.2015.03.007

51. Wang KC, Chang HY (2011) Molecular mechanisms of long non-coding RNAs. Mol Cell 43:904–914. https://doi.org/10.1016/j.molcel.2011.08.018

52. Blythe AJ, Fox AH, Bond CS (2016) The ins and outs of lncRNA structure: How, why and what comes next? Biochim Biophys Acta 1859:46–58. https://doi.org/10.1016/j.bbabmb.2015.08.009

53. Amin V, Harris RA, Onuchic V, Jackson AR, Charnecki T, Paitthnark S, Lakshmi Subramanian S, Riehle K, Coarfa C, Milosavljevic A (2015) Epigenomic footprints across 111 reference epigenomes reveal tissue-specific epigenetic regulation of lincRNAs. Nat Commun 6:6370. https://doi.org/10.1038/ncomms7370

54. Yuan T, Huang X, Woodcock M, Du M, Dittmar R, Wang Y, Tsai S, Kohli M, Boardman L, Patel T, Wang L (2016) Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep 6:19413. https://doi.org/10.1038/srep19413

55. Umu SU, Langseth H, Bucher-Johannessen C, Fromm B, Keller A, Meese E, Lauritzen M, Leithaug M, Lyle R, Rounge TB (2018) A comprehensive profile of circulating RNAs in human serum. RNA Biol 15:242–250. https://doi.org/10.1080/15476286.2017.1403003

56. Sun Q, Hao Q, Prasanth KV (2018) Nuclear long noncoding RNAs: Key regulators of gene expression. Trends Genet 34:142–157. https://doi.org/10.1016/j.tig.2017.11.005

57. Noh JH, Kim KM, McClusky WG, Abdelmohsen K, Gorospe M (2018) Cytoplasmic functions of long noncoding RNAs. Wiley Interdiscip Rev RNA 9:e1471. https://doi.org/10.1002/wrna.1471

58. Belokhvatsova D, Bezranksyte I, Cujba AM, Jowett G, Marshall L, Prueller J, Watt FM (2018) Homeostasis, regeneration and tumour formation in the mammalian epidermis. Int J Dev Biol 62:571–582. https://doi.org/10.1387/ijdb.170341fw

59. Fuchs E (2006) Skin stem cells: rising to the surface. J Cell Biol 180:273–284. https://doi.org/10.1083/jcb.200708185

60. Miroshnikova YA, Le HQ, Schneider D, Thalheim T, Rübasm M, Bremicker N, Polleux J, Kampnad P, Tarantola M, Wang I, Baland M, Niessen CM, Galie J, Wickstrom SA (2018) Adhesion forces and cortical tension couple cell proliferation and differentiation to drive epidermal stratification. Nat Cell Biol 20:69–80. https://doi.org/10.1038/s41556-017-0005-z
61. Kypriotou M, Huber M, Hohl D (2012) The human epidermal differentiation complex: cornified envelope precursors, S100 proteins and the ‘fused genes’ family. Exp Dermatol 21:643–649. https://doi.org/10.1111/j.1600-0625.2012.01472.x
62. Cavazza A, Miccio A, Romano O, Petiti L, Malagoli Tagliazucchi G, Peano C, Severgnini M, Rizzi E, De Bellis G, Bicciafo S, Mavilio F (2016) Dynamic transcriptional and epigenetic regulation of human epidermal keratinocyte differentiation. Stem Cell Reports 6:618–632. https://doi.org/10.1016/j.stemcr.2016.03.003
63. Rubin AJ, Barajas BC, Furlan-Magaril M, Lopez-Pajares V, Mumbach MR, Howard I, Kim DS, Boxer LD, Cairns J, Spivakov M, Wingett SW, Shi M, Zhao Z, Greenleaf WJ, Kundaje A, Snyder M, Chang HY, Fraser P, Khavari PA (2017) Lineage-specific dynamic and pre-established enhancer-promoter contacts cooperate in terminal differentiation. Nat Genet 49:1522–1528. https://doi.org/10.1038/ng.3935
64. Mazar J, Sinha S, Dinger ME, Mattick JS, Perera RJ (2015) Protein-coding and non-coding gene expression analysis in differentiating human keratinocytes using a three-dimensional epidermal equivalent. Mol Genet Genomics 284:1–9. https://doi.org/10.1007/s00438-010-0543-6
65. Örom UA, Derrien T, Guigo R, Shiekhattar R (2010) Long noncoding RNAs as enhancers of gene expression. Cold Spring Harb Symp Quant Biol 75:325–331. https://doi.org/10.1101/sqb.2010.75.058
66. Kretz M, Webster DE, Flochhart RJ, Lee CS, Zehnder A, Lopez-Pajares V, Qu K, Zheng GX, Chow J, Kim GE, Rinn JL, Chang HY, Siprashvili Z, Khavari PA (2012) Suppression of progenitor differentiation requires the long noncoding RNA ANCR. Genes Dev 26:338–343. https://doi.org/10.1101/gad.182121.111
67. Lopez-Pajares V, Qu K, Zhang J, Webster DE, Barajas BC, Siprashvili Z, Harb Symp Quant Biol 75:22–34. https://doi.org/10.1101/gad.182122.111
68. Kretz M, Siprashvili Z, Chu C, Webster DE, Zehnder A, Qu K, Lee CS, Flochhart RJ, Groff AF, Chow J, Johnston D, Kim GE, Spilute RC, Flynn RA, Zheng GX, Aiyer S, Raj A, Rinn JL, Chang HY, Khavari PA (2015) A LncRNA-MAF:MAFB transcription factor network regulates epidermal differentiation. Dev Cell 32:693–706. https://doi.org/10.1016/j.devcel.2015.01.028
69. Kretz M, Siprashvili Z, Harb Symp Quant Biol 75:228–234. https://doi.org/10.1101/gad.182123.111
70. Ziegler C, Graf J, Faderl S, Flockhart RJ, Lee CS, Zehnder A, Lopez-Pajares V, Qu K, Zheng GX, Chow J, Kim GE, Rinn JL, Chang HY, Siprashvili Z, Khavari PA (2012) Suppression of progenitor differentiation requires the long noncoding RNA ANCR. Genes Dev 26:338–343. https://doi.org/10.1101/gad.182121.111
71. Jones PH, Watt FM (1993) Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 73:713–724. https://doi.org/10.1016/0009-8684(93)90251-K
72. Tanis SEJ, Koekal ES, van Buggenum JAGL, Mulder KW (2019) The long non-coding RNA LINC00941 and SPRR5 are novel regulators of human epidermal homeostasis. EMBO Rep 20:e46612. https://doi.org/10.15252/embr.201846612
73. Jones PH, Watt FM (1993) Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 73:713–724. https://doi.org/10.1016/0009-8684(93)90251-K
74. Cai P, Otten ABC, Cheng B, Ishii MA, Zhang W, Huang B, Qu K, Sun BK (2020) A genome-wide long noncoding RNA CRISPR screen identifies PRANCR as a novel regulator of epidermal homeostasis. Genome Res 30:22–34. https://doi.org/10.1101/gr.251561.119
75. Li CX, Li HG, Huang LT, Kong YW, Chen FY, Liang JY, Yu H, Yao ZR (2019) H19 IncRNA regulates keratocin differentiation by targeting miR-130b-3p. Cell Death Dis 8:e3174. https://doi.org/10.1038/cddis.2017.516
76. Lee CS, Mah A, Aros CJ, Lopez-Pajares V, Bhaduri A, Webster DE, Kretz M, Khavari PA (2018) Cancer-associated long noncoding RNA SMRT-2 controls epidermal differentiation. J Invest Dermatol 138:1445–1449. https://doi.org/10.1016/j.jid.2018.01.003
77. Sen GL, Boxer LD, Webster DE, Bussat RT, Qu K, Zarnegar BJ, Johnston D, Siprashvili Z, Khavari PA (2012) ZNF750 is a p63 target gene that induces KLF4 to drive terminal epidermal differentiation. Dev Cell 22:669–677. https://doi.org/10.1016/j.devcel.2011.12.001
78. Hazawa M, Lin DC, Handral H, Xu L, Chen Y, Jiang YY, Mayakonda A, Ding LW, Meng X, Sharma A, Samuel S, Movahednia MM, Wong RW, Yang H, Tong C, Koeffler HP (2017) ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma. Oncogene 36:2243–2254. https://doi.org/10.1038/onc.2016.377
79. Thieu K, Ruiz ME, Owens DM (2013) Cells of origin and tumor-initiating cells for nonmelanoma skin cancers. Cancer Lett 338:82–88. https://doi.org/10.1016/j.canlet.2012.05.008
80. Kuri P, Rompolas P (2018) Differentiation keeps skin cancer at bay. Nat Cell Biol 20:1237–1239. https://doi.org/10.1038/s41598-018-0222-0
81. Ponzi G, Zuizzerio R, Bourget I, Allan R, Nottet N, Popa A, Magnone V, Rios G, Mari B, Barbry P (2017) A new long noncoding RNA (lncRNA) is induced in cutaneous squamous cell carcinoma and down-regulates several anticancer and cell differentiation genes in mouse. J Biol Chem 292:12483–12495. https://doi.org/10.1074/jbc.M117.776260
82. Toriseva M, Kähärä VM (2009) Proteinases in cutaneous wound healing. Cell Mol Life Sci 66:203–224. https://doi.org/10.1007/s00438-009-0883-4
83. Cooper DR, Wang C, Patel R, Trujillo A, Patel NA, Prather J, Gould LJ, Wu MH (2018) Human adipose-derived stem cell conditioned media and exosomes containing MALAT1 promotes wound healing by inhibiting the transcription factor e-Myc via the glucocorticoid receptor and the long non-coding RNA Gas5. J Biol Chem 293:1439–1449. https://doi.org/10.1074/jbc.M117.811240
84. Zhang X, Hamblin MH, Yin KJ (2017) The long noncoding RNA Malat 1: its physiological and pathophysiological functions. RNA Biol 14:1705–1714. https://doi.org/10.1080/15472261.2017.1358347
85. Cooper DR, Wang C, Patel R, Trujillo A, Patel NA, Prather J, Gould LJ, Wu MH (2018) Human adipose-derived stem cell conditioned media and exosomes containing MALAT1 promote human dermal fibroblast migration and ischemic wound healing. Adv Wound Care (New Rochelle) 7:299–308. https://doi.org/10.1089/wound.2017.0775
86. Liu Z, Ren L, Tian J, Liu N, Hu Y, Zhang P (2018) Comprehensive analysis of long noncoding RNAs and messenger RNAs expression profiles in patients with Marjolin ulcer. Med Sci Monit 24:7828–7840. https://doi.org/10.12659/MSM.911177
87. Thieu K, Ruiz ME, Owens DM (2013) Cells of origin and tumor-initiating cells for nonmelanoma skin cancers. Cancer Lett 338:82–88. https://doi.org/10.1016/j.canlet.2012.05.008
88. Tao SC, Rui BY, Wang QY, Zhou D, Zhang Y, Guo SC (2018) Extracellular vesicle-mimetic nanovesicles transport LncRNA-motn.2019.05.020
89. Tao SC, Rui BY, Wang QY, Zhou D, Zhang Y, Guo SC (2018) Extracellular vesicle-mimetic nanovesicles transport LncRNA-H19 as competing endogenous RNA for the treatment of diabetic wounds. Drug Deliv 25:241–255. https://doi.org/10.1080/10717444.2018.1425774
89. Guo JR, Yin L, Chen YQ, Jin XJ, Zhou X, Zhu NN, Liu XQ, Wei HW, Duan LS (2018) Autologous blood transfusion augments impaired wound healing in diabetic mice by enhancing lncRNA H19 expression via the HIF-1α signaling pathway. Cell Commun Signal 16:84. https://doi.org/10.1186/s12964-018-0290-6

90. Li D, Kular L, Vij M, Herter EK, Li X, Chu T, Toma MA, Zhang L, Liapi E, Mota A, Blomqvist L, Gallais Séraléz I, Rollman O, Wikstrom JD, Bienen M, Berglund D, Ståhle M, Sommer P, Jagodic M, Landén NX (2019) Human skin long non-coding RNA WAKMAR1 regulates wound healing by enhancing keratinocyte migration. Proc Natl Acad Sci USA 116:9443–9452. https://doi.org/10.1073/pnas.1814097116

91. Herter EK, Li D, Toma MA, Vij M, Li X, Visscher D, Wang A, Chu T, Sommer P, Blomqvist L, Berglund D, Ståhle M, Wikstrom JD, Xu Landén N (2019) WAKMAR2, a long non-coding RNA downregulated in human chronic wounds, modulates keratinocyte motility and production of inflammatory chemokines. J Invest Dermatol 139:1373–1384. https://doi.org/10.1016/j.jid.2018.11.033

92. Bernard JJ, Gallo RL, Krutmann J (2019) Photoimmunology: how ultraviolet radiation affects the immune system. Nat Rev Immunol 19:688–701. https://doi.org/10.1038/s41577-019-0185-9

93. Chen H, Weng QY, Fisher DE (2014) UV signaling pathways within the skin. J Invest Dermatol 134:2080–2085. https://doi.org/10.1038/jid.2014.161

94. Kripke ML, Cox PA, Alas LG, Yarosh DB (1992) Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice. Proc Natl Acad Sci USA 89:7516–7520. https://doi.org/10.1073/pnas.89.16.7516

95. Vink AA, Moodycliffe AM, Shreedhar V, Ulrich SE, Roza L, Yarosh DB, Kripke ML (1997) The inhibition of antigen-presenting activity of dendritic cells resulting from UV irradiation of murine skin is restored by in vitro photorepair of cyclobutane pyrimidine dimers. Proc Natl Acad Sci USA 94:5255–5260. https://doi.org/10.1073/pnas.94.10.5255

96. Garssen J, van Steeg H, de Gruijl F, de Boer J, van der Horst GT, van Kranen H, van Loveren H, van Dijk M, Fluitman A, Weeda G, Hoeijmakers JH (2000) Transcription-coupled and global genome repair differentially influence UV-B-induced acute skin effects and systemic immunosuppression. J Immunol 164:6199–6205. https://doi.org/10.4049/jimmunol.164.12.6199

97. Vieyra-Garcia PA, Wolf P (2018) From early immunomodulatory events to therapeutic implications of the complex interplay between the wavebands of sunlight and the skin. Front Med (Lausanne) 5:232. https://doi.org/10.3389/fmed.2018.00232

98. Kim KH, Kim HJ, Lee TR (2017) Epidermal long non-coding RNAs are regulated by ultraviolet irradiation. Gene 637:196–202. https://doi.org/10.1016/j.gene.2017.09.043

99. Zeng Q, Wang Q, Chen X, Xia K, Tang J, Zhou X, Cheng Y, Chen Y, Huang L, Xiang H, Cao K, Zhou J (2016) Analysis of lncRNAs expression in UVB-induced stress responses of melanocytes. J Dermatol Sci 81:53–60. https://doi.org/10.1016/j.jdermsci.2015.10.019

100. Zheng Y, Xu Q, Peng Y, Gong Z, Chen H, Lai W, Maibach HI (2017) Expression profiles of long noncoding RNA in UV-A-induced human skin fibroblasts. Skin Pharmacol Physiol 30:315–323. https://doi.org/10.1159/000477972

101. Yo K, Rünger TM (2017) UVA and UVB induce different sets of long noncoding RNAs. J Invest Dermatol 137:769–772. https://doi.org/10.1016/j.jid.2016.10.041

102. Peng Y, Song X, Zheng Y, Wang X, Lai W (2017) Circular RNA profiling reveals that circCOL3A1-859267 regulate type I collagen expression in photoaged human dermal fibroblasts. Biochem Biophys Res Commun 486:277–284. https://doi.org/10.1016/j.brc.2017.03.028

103. Lei L, Zeng Q, Lu J, Ding S, Xia F, Kang J, Tan L, Gao L, Kang L, Cao K, Zhou J, Xiao R, Chen J, Huang J (2017) MALAT1 participates in ultraviolet B-induced photo-aging via regulation of the ERK/MAPK signaling pathway. Mol Med Rep 15:3977–3982. https://doi.org/10.3892/mmr.2017.6532

104. Sonkoly E, Bata-Csorgo Z, Pivarcsi A, Polyanika H, Kenderessy-Szabo A, Molnar G, Szentpali K, Bari L, Megyeri K, Mandy I, Dobozy A, Kemeny L, Szell M (2005) Identification and characterization of a novel, psoriasis susceptibility-related noncoding RNA gene, PRINS. J Biol Chem 280:24159–24167. https://doi.org/10.1074/jbc.M501704200

105. Hall JR, Messenger ZJ, Tam HW, Phillips SL, Recio L, Smart RC (2015) Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes. Cell Death Dis 6:e1700. https://doi.org/10.1038/cddis.2015.67

106. Jin S, Yang X, Li J, Yang W, Ma H, Zhang Z (2019) p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma. Mol Cancer 18:38. https://doi.org/10.1186/s12943-019-0993-3

107. Reichrath J, Saternus R, Vogt T (2017) Endocrine actions of vitamin D in skin: Relevance for photocarcinogenesis of non-melanoma skin cancer, and beyond. Mol Cell Endocrinol 453:96–102. https://doi.org/10.1016/j.mce.2017.05.001

108. Jiang YJ, Bickle DD (2014) LncRNA: a new player in 1α, 25(OH)(2) vitamin D3) /VDR protection against skin cancer formation. Exp Dermatol 23:147–150. https://doi.org/10.1111/exd.12341

109. Sand M, Bechara FG, Sand D, Gambichler T, Hahn SA, Bromba M, Stockfleth E, Hessam S (2016) Expression profiles of long noncoding RNAs in cutaneous squamous cell carcinoma. Epigenomics 8:501–518. https://doi.org/10.2217/epi-2015-0012

110. Piipponen M, Nissinen L, Farshchian M, Rihilä P, Kivisaari A, Kallajoki M, Peltonen J, Peltonen S, Kähäri VM (2016) Long noncoding RNA PICSAR promotes growth of cutaneous squamous cell carcinoma. Epigenomics 8:510–512. https://doi.org/10.2217/epi-2015-0012

111. Lambert SR, Mladkova N, Gulati A, Hamoudi R, Purdie K, Volders PJ, Lefever S, Menten B, Vandesompele J (2018) Targeted genomic screen reveals focal long non-coding RNA copy number alterations in cancer cell lines. Noncoding RNA 4:E21. https://doi.org/10.1371/journal.pgen.1003201

112. Kumar V, Westra HJ, Karjalainen J, Zherнакова DV, Esko T, Hrdlickova B, Almeida R, Zherнакова A, Reinmaa E, Võsa U, Hofker MH, Feinmann RS, Fu J, Withof S, Metspalu A, Franke L, Wijmenga C (2013) Human disease-associated genetic variation impacts large intergenic non-coding RNA expression. PLoS Genet 9:e1003201. https://doi.org/10.1371/journal.pgen.1003201

113. Lambert SR, Mladkova N, Gulati A, Hamoudi R, Purdie K, Volders PJ, Lefever S, Menten B, Vandesompele J (2018) Targeted genomic screen reveals focal long non-coding RNA copy number alterations in cancer cell lines. Noncoding RNA 4:E21. https://doi.org/10.1371/journal.pgen.1003201

114. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Sleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Oette NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Nolop KB, Lee RJ, Aker AO, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Ros MA, Lo RS, Ribas A, Marais R (2012) RAS mutations in cutaneous biology and keratinocyte carcinomas.
squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207–215. https://doi.org/10.1056/NEJMoai1105358

115. Einspahr JG, Calvert V, Alberts DS, Curiel-Lewandrowski C, Warneke J, Krouse J, Stratton SP, Liotta L, Longo C, Pellacani G, Prasad A, Sagerman P, Bermudez Y, Deng J, Bowden GT, Petricoin EF 3rd (2012) Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma. Cancer Prev Res (Phila) 5:403–413. https://doi.org/10.1158/1940-6207.CAPR-11-0427

116. Bachelor MA, Bowden GT (2004) UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. Semin Cancer Biol 14:131–138. https://doi.org/10.1016/j.semcancer.2003.09.017

117. Wei P, Wang Z (2017) Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) 9:652. https://doi.org/10.3390/cancers9050052

118. Piipponen M, Heino J, Kähäri VM, Nissinen L (2018) Long non-coding RNA PICSAR decreases adhesion and promotes migration of squamous carcinoma cells by downregulating α2β1 and α5β1 integrin expression. Biol Open 7:bio037044. https://doi.org/10.1242/bio.037044

119. Zhang Y, Gao L, Ma S, Ma J, Wang Y, Li S, Hu X, Han S, Zhou M, Zhou L, Ding Z (2019) MALAT1-KTN1-EGFR regulatory axis promotes the development of cutaneous squamous cell carcinoma. Cell Death Differ 26:2061–2073. https://doi.org/10.1038/s41418-019-0288-7

120. Nassar D, Latil M, Boeckx B, Lambrechts D, Blanpain C (2015) Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nat Med 21:946–954. https://doi.org/10.1038/nm.3878

121. Casanova ML, Larcher F, Casanova B, Murillas R, Fernández-Aceñero MJ, Villanueva C, Martínez-Palacio J, Ullrich A, Conti CJ, Jorcano JL (2002) A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 62:3402–3407

122. Dlugosz AA, Cheng C, Williams KE, Darwiche N, Dempsey PJ, Mann B, Dunn AR, Coffey RJ Jr, Yuspa SH (1995) Autocrine transforming growth factor alpha is dispensable for v-rasHa-induced epidermal neoplasia: potential involvement of alternate epidermal growth factor receptor ligands. Cancer Res 55:1883–1893

123. Mei XL, Zhong S (2019) Long noncoding RNA LINC00520 prevents the progression of cutaneous squamous cell carcinoma through the inactivation of the PI3K/Akt signaling pathway by downregulating EGFR. Chin Med J (Engl) 132:454–465. https://doi.org/10.1097/CM9.0000000000000070

124. Merlino GT, Xu YH, Ishii S, Clark AJ, Semba K, Toyoshima K, Yamamoto T, Pastan I (1984) Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science 224:417–419. https://doi.org/10.1126/science.6200934

125. Rognioni E, Walko G (2019) The roles of YAP/TAZ and the Hippo pathway in healthy and diseased skin. Cells 8:E411. https://doi.org/10.3390/cells805041

126. Chen L, Chen Q, Kuang S, Zhao C, Yang L, Zhang Y, Zhu H, Yang R (2019) USF1-induced upregulation of LINC01048 promotes cell proliferation and apoptosis in cutaneous squamous cell carcinoma by binding to TAF15 to transcriptionally activate YAP1. Cell Death Dis 10:296. https://doi.org/10.1038/s41419-019-1516-2

127. Muroishi T, Hansen CG, Guan KL (2015) The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 15:73–79. https://doi.org/10.1038/nrc3876

128. Debaugnies M, Sánchez-Danés A, Rorive S, Raphael M, Liagre M, Parent MA, Brisebarre A, Salmon I, Blanpain C (2018) YAP and TAZ are essential for basal and squamous cell carcinoma initiation. EMBO Rep 19:e45809. https://doi.org/10.15252/embr.201845809

129. Piipponen M, Nissinen L, Riihilä P, Farshchian M, Kallajoki M, Peltonen J, Peltonen S, Kähäri VM (2019) p53-regulated long non-coding RNA PRECSIT promotes progression of cutaneous squamous cell carcinoma via STAT3 signaling. Am J Pathol 190:503–517. https://doi.org/10.1016/j.ajpath.2018.10.019

130. Li F, Liao J, Duan X, He Y, Liao Y (2018) Upregulation of LINC00319 indicates a poor prognosis and promotes cell proliferation and invasion in cutaneous squamous cell carcinoma. J Cell Biochem 119:10393–10405. https://doi.org/10.1002/jcb.27388

131. Sand M, Bechara FG, Sand D, Gambichler T, Hahn SA, Bromba M, Stockfleth E, Hessam S (2016) Long-noncoding RNAs in basal cell carcinoma. Tumor Biol 37(8):10595–10608. https://doi.org/10.1007/s13277-016-4927-z

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.